Verpakking van 10 flacons6 op voorraadBespaar 19%Retatrutide 50 mg
Tri-agonist GLP-1 / GIP / glucagon-onderzoekspeptide
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Uitsluitend voor onderzoeksdoeleinden. Deze verbinding wordt strikt verkocht voor in-vitro-onderzoek en laboratoriumdoeleinden en is niet bestemd voor menselijke consumptie of therapeutisch gebruik. Door te kopen bevestigt u dat u een gekwalificeerde onderzoeker bent en gaat u akkoord met onze volledige disclaimer.
Nog maar 6 verpakkingen
Onderzoekspeptide met drievoudige-receptoragonisme, bestudeerd vanwege gecombineerde effecten op de signaalroutes van GLP-1, GIP en glucagon in metabole onderzoekstoepassingen.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mechanisme
Bestudeerd vanwege gelijktijdig agonisme van GLP-1-, GIP- en glucagonreceptoren. Onderzoek geassocieerd met markers van stofwisselingssnelheid, verzadiging en energieverbruik in onderzoekspopulaties.
HPLC-geverifieerd tegen een zuiverheidsspecificatie van ≥99 %. Onafhankelijk getest door geaccrediteerde derdenlaboratoria.
Retatrutide — veelgestelde vragen
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Gidsen over Retatrutide
Onderzoekers bekijken ook
Verpakking van 10 flaconsBespaar 22%MOTS-c
Gelyofiliseerd poeder10 mg · 2 strengths
Mitochondriaal afgeleid metabool peptide
In 2 combinaties
Verpakking van 10 flaconsBespaar 16%5-Amino-1MQ
Gelyofiliseerd poeder50 mg · 3 strengths
NNMT-remmer onderzoeksverbinding
Verpakking van 10 flaconsBespaar 15%L-Carnitine
Sterile solution10 ml × 600 mg/ml
Mitochondriale vetzuurtransporter
In 1 combinatie